ATE521606T1 - Quaternäre ammoniumsalze als m3-antagonisten - Google Patents
Quaternäre ammoniumsalze als m3-antagonistenInfo
- Publication number
- ATE521606T1 ATE521606T1 AT05820639T AT05820639T ATE521606T1 AT E521606 T1 ATE521606 T1 AT E521606T1 AT 05820639 T AT05820639 T AT 05820639T AT 05820639 T AT05820639 T AT 05820639T AT E521606 T1 ATE521606 T1 AT E521606T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- quaternary ammonium
- ammonium salts
- compounds
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428418.8A GB0428418D0 (en) | 2004-12-24 | 2004-12-24 | Organic compounds |
| PCT/EP2005/013897 WO2006066929A1 (de) | 2004-12-24 | 2005-12-22 | Scannerkopf und bearbeitungsmaschine damit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521606T1 true ATE521606T1 (de) | 2011-09-15 |
Family
ID=34130968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05820639T ATE521606T1 (de) | 2004-12-24 | 2005-12-22 | Quaternäre ammoniumsalze als m3-antagonisten |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8153669B2 (de) |
| EP (1) | EP1831208B1 (de) |
| JP (1) | JP2008525359A (de) |
| KR (1) | KR101259654B1 (de) |
| CN (1) | CN101080405B (de) |
| AT (1) | ATE521606T1 (de) |
| AU (1) | AU2005318424B2 (de) |
| BR (1) | BRPI0519292A2 (de) |
| CA (1) | CA2589133A1 (de) |
| ES (1) | ES2370832T3 (de) |
| GB (1) | GB0428418D0 (de) |
| HK (1) | HK1109767A1 (de) |
| MX (1) | MX2007007722A (de) |
| PL (1) | PL1831208T3 (de) |
| PT (1) | PT1831208E (de) |
| RU (1) | RU2394031C2 (de) |
| WO (1) | WO2006066929A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| BRPI0807615A8 (pt) | 2007-02-23 | 2017-12-05 | Theravance Inc | Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico |
| CN101796026B (zh) | 2007-09-07 | 2013-10-23 | 施万制药 | 可用作毒蕈碱受体拮抗剂的含胍化合物 |
| EP2222637A1 (de) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidinhaltige verbindungen als muscarinrezeptor-antagonisten |
| DE102008020746A1 (de) * | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| JP6363616B2 (ja) | 2012-12-19 | 2018-07-25 | ノバルティス アーゲー | オートタキシン阻害剤 |
| TR201808040T4 (tr) | 2013-03-15 | 2018-06-21 | Bodor Laboratories Inc | Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler. |
| JPWO2015122031A1 (ja) * | 2014-02-17 | 2017-03-30 | 株式会社Ｌｔｔバイオファーマ | メペンゾラート光学活性体及びそれを有効成分とする慢性閉塞性肺疾患改善剤 |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US20170037030A1 (en) | 2014-04-24 | 2017-02-09 | Novartis Ag | Autotaxin inhibitors |
| US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
| CA2963422A1 (en) | 2014-10-03 | 2016-04-07 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
| EP3325487B1 (de) | 2015-07-21 | 2021-05-05 | Bodor Laboratories, Inc. | Formulierung für weiche anticholinergische analoga |
| TWI767507B (zh) | 2016-07-21 | 2022-06-11 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| AU2021236130A1 (en) * | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JPS6018661B2 (ja) | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体 |
| JPS5427570A (en) | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| JPS5835177A (ja) | 1981-08-26 | 1983-03-01 | Dainippon Pharmaceut Co Ltd | ２−環状アミノ−２−（１，２−ベンズイソキサゾ−ル−３−イル）酢酸エステル類並びにその酸付加塩類および第４級アンモニウム塩類 |
| JPS58208270A (ja) | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類 |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| RU2238936C2 (ru) | 1996-11-11 | 2004-10-27 | Кристиан Р. НОЕ | Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах |
| WO2002004402A1 (fr) * | 2000-07-11 | 2002-01-17 | Banyu Pharmaceutical Co., Ltd. | Derives d'ester |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| EP1583741A1 (de) * | 2002-12-23 | 2005-10-12 | Ranbaxy Laboratories, Limited | 1-substituierte-3-pyrrolidin-derivate als muscarinrezeptor-antagonisten |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1781607A2 (de) * | 2004-08-19 | 2007-05-09 | Ranbaxy Laboratories Limited | Pyrrolidinderivate als antagonisten des muscarinrezeptors |
-
2004
- 2004-12-24 GB GBGB0428418.8A patent/GB0428418D0/en not_active Ceased
-
2005
- 2005-12-22 CN CN2005800429764A patent/CN101080405B/zh not_active Expired - Fee Related
- 2005-12-22 KR KR1020077014261A patent/KR101259654B1/ko not_active IP Right Cessation
- 2005-12-22 EP EP05820639A patent/EP1831208B1/de not_active Not-in-force
- 2005-12-22 US US11/721,989 patent/US8153669B2/en not_active Expired - Fee Related
- 2005-12-22 BR BRPI0519292-7A patent/BRPI0519292A2/pt not_active IP Right Cessation
- 2005-12-22 ES ES05820639T patent/ES2370832T3/es active Active
- 2005-12-22 PT PT05820639T patent/PT1831208E/pt unknown
- 2005-12-22 CA CA002589133A patent/CA2589133A1/en not_active Abandoned
- 2005-12-22 PL PL05820639T patent/PL1831208T3/pl unknown
- 2005-12-22 RU RU2007128085/04A patent/RU2394031C2/ru not_active IP Right Cessation
- 2005-12-22 AT AT05820639T patent/ATE521606T1/de active
- 2005-12-22 AU AU2005318424A patent/AU2005318424B2/en not_active Ceased
- 2005-12-22 WO PCT/EP2005/013897 patent/WO2006066929A1/de active Application Filing
- 2005-12-22 JP JP2007547368A patent/JP2008525359A/ja active Pending
- 2005-12-22 MX MX2007007722A patent/MX2007007722A/es active IP Right Grant
-
2008
- 2008-01-14 HK HK08100466.7A patent/HK1109767A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005318424A1 (en) | 2006-06-29 |
| MX2007007722A (es) | 2007-08-14 |
| CN101080405A (zh) | 2007-11-28 |
| ES2370832T3 (es) | 2011-12-23 |
| EP1831208A1 (de) | 2007-09-12 |
| KR101259654B1 (ko) | 2013-04-30 |
| US20090227590A1 (en) | 2009-09-10 |
| KR20070089953A (ko) | 2007-09-04 |
| CN101080405B (zh) | 2011-05-11 |
| RU2394031C2 (ru) | 2010-07-10 |
| JP2008525359A (ja) | 2008-07-17 |
| CA2589133A1 (en) | 2006-06-29 |
| BRPI0519292A2 (pt) | 2009-01-06 |
| US8153669B2 (en) | 2012-04-10 |
| EP1831208B1 (de) | 2011-08-24 |
| PL1831208T3 (pl) | 2012-01-31 |
| AU2005318424B2 (en) | 2009-10-08 |
| WO2006066929A1 (de) | 2006-06-29 |
| PT1831208E (pt) | 2011-10-31 |
| RU2007128085A (ru) | 2009-01-27 |
| GB0428418D0 (en) | 2005-02-02 |
| HK1109767A1 (en) | 2008-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521606T1 (de) | Quaternäre ammoniumsalze als m3-antagonisten | |
| ATE541839T1 (de) | Pyrrolidiniumderivate als m3-muskarinische rezeptoren | |
| TW200505920A (en) | Organic compounds | |
| JO2613B1 (ar) | مركبات عضوية | |
| TW200617009A (en) | Organic compounds | |
| TW200519106A (en) | Organic compounds | |
| ES2368594T3 (es) | Derivados sustituidos de ciclohexilmetilo. | |
| MX2009004715A (es) | Compuestos heterociclicos como agentes antiinflamatorios. | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| MA28550B1 (fr) | Composes et procedes permettant de traiter la dyslipidemie | |
| TW200745056A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| MXPA05013823A (es) | Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico. | |
| DE602005007064D1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора | |
| TNSN06410A1 (en) | Pyrrolopyridine derivatives and their use as crth2 antagonists | |
| TNSN05279A1 (en) | Quinuclidine derivatives binding to mucarinic m3 receptors | |
| DE602005015866D1 (de) | Azetidin-derivate als ccr-3-rezeptor-antagonisten | |
| ATE488497T1 (de) | Pyrrolidinderivate, die als antagonisten des ccr3-rezeptors wirken | |
| ECSP045288A (es) | Derivados de azetidina como antagonistas del receptor ccr-3 | |
| TH97394A (th) | แอริลเอไมด์ที่ถูกแทนที่ด้วยเททราโซล | |
| TH97394B (th) | แอริลเอไมด์ที่ถูกแทนที่ด้วยเททราโซล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1831208 Country of ref document: EP |